XBioTech Inc: Surges to near 5-yr high on $420 mln share repurchase
** Drug developer's XBIT.O shares jump 41.8% to $26.40 -
highest since Apr 2015
** Company starts a tender process to buyback $420 mln worth
of its shares at $30-$33 per share in cash — a premium of
61%-77% to its closing price on Monday urn:newsml:reuters.com:*:nGNX5VcZtZ
** Company says its "modified Dutch auction" offer expires
on Feb. 12, 2020 at 5 p.m. ET, unless extended
** Offer not contingent upon company receiving any financing
- XBIT
** Stock had more than tripled in 2019
(Reporting by Ruhi Soni in Bengaluru)
((Ruhi.Soni@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke